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Abstract
Over two-thirds of the world’s population lives in regions where rabies is endemic, resulting in over 15 million people
receiving multi-dose post-exposure prophylaxis (PEP) and over 55,000 deaths per year globally. A major goal in rabies virus
(RABV) research is to develop a single-dose PEP that would simplify vaccination protocols, reduce costs associated with
RABV prevention, and save lives. Protection against RABV infections requires virus neutralizing antibodies; however, factors
influencing the development of protective RABV-specific B cell responses remain to be elucidated. Here we used a mouse
model of IL-21 receptor-deficiency (IL-21R2/2) to characterize the role for IL-21 in RABV vaccine-induced immunity. IL-
21R2/2 mice immunized with a low dose of a live recombinant RABV-based vaccine (rRABV) produced only low levels of
primary or secondary anti-RABV antibody response while wild-type mice developed potent anti-RABV antibodies.
Furthermore, IL-21R2/2 mice immunized with low-dose rRABV were only minimally protected against pathogenic RABV
challenge, while all wild-type mice survived challenge, indicating that IL-21R signaling is required for antibody production in
response to low-dose RABV-based vaccination. IL-21R2/2 mice immunized with a higher dose of vaccine produced
suboptimal anti-RABV primary antibody responses, but showed potent secondary antibodies and protection similar to wild-
type mice upon challenge with pathogenic RABV, indicating that IL-21 is dispensable for secondary antibody responses to
live RABV-based vaccines when a primary response develops. Furthermore, we show that IL-21 is dispensable for the
generation of Tfh cells and memory B cells in the draining lymph nodes of immunized mice but is required for the detection
of optimal GC B cells or plasma cells in the lymph node or bone marrow, respectively, in a vaccine dose-dependent manner.
Collectively, our preliminary data show that IL-21 is critical for the development of optimal vaccine-induced primary but not
secondary antibody responses against RABV infections.
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Introduction
RABV is a single-stranded negative sense RNA virus of the
genus lyssavirus in the Rhabdoviridae family that kills approximately
55,000 people annually. Up to 60% of rabies cases are in children,
making rabies the seventh most important infectious disease in
terms of years lost [1]. In Africa, a person dies of rabies every
20 minutes [2]. In China, rabies became the leading cause of
infectious disease mortality in 2006, which increased by more than
27% from 2005 [3]. In the United States, cases of rabies in wildlife
are detected in virtually all states and Puerto Rico (Hawaii is
considered rabies-free). Except for cattle and foxes, the incidence
of rabies in domesticated or wildlife remained unchanged or
significantly increased in the US in 2011 compared to the five-year
average for each species [4], exemplifying the difficulty in
containing zoonotic viral infections even in industrialized nations.
The cost associated with rabies in the US, Africa and Asia is
almost $1 billion annually [5,6] contributing to the financial
burden of global health care costs. Furthermore, rabies is a NIAID
Category C Priority Pathogen, indicating rabies is an emerging
infectious disease with the potential for mass dissemination and
harm to people [7]. Together, rabies is considered a neglected
global zoonotic infectious disease that disproportionately affects
children and, therefore, understanding how B cells develop in
response to experimental RABV-based vaccination may help to
support efforts to develop a single-dose human rabies vaccine for
use in both developing and industrialized countries.
A wide array of RABV variants exist, ranging from highly
pathogenic strains to attenuated RABV vaccine strains such as the
molecular clone SAD B19 [8]. Live attenuated RABV vaccine
strains are highly immunogenic and potentially could serve as a
single-dose human RABV vaccine to replace currently used multi-
dose inactivated RABV-based vaccine regimens. Due to residual
pathogenicity of these live virus strains, however, several ‘‘second-
generation’’ RABV-based vaccines are under investigation in
which entire genes are deleted from the RABV genome [9–12], or
multiple pathogenic markers are genetically modified [13]. Data
from these studies indicate that very safe and effective live RABV-
based vaccine vectors can be generated. Despite extensive efforts
to attenuate live RABV-based vaccine vectors for safety, little
information is available on factors that influence the generation of
effective antibodies in response to live RABV-based vaccines.
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Virus neutralizing antibodies (IgG but not IgM) directed against
the RABV glycoprotein (G) are protective against pathogenic
RABV strains [14,15]. In the case of a replication-deficient
RABV-based vaccine in which the matrix gene is deleted, VNAs
are generated by T cell-independent and –dependent (extrafolli-
cular and germinal center) mechanisms [16], suggesting multiple
pathways of B cell activation and differentiation could be exploited
to rationally design a single-dose RABV vaccine for use in both
pre- and post-exposure settings. With respect to typical vaccine-
induced antibody responses, APC-primed T cells most likely
display an intermediate Tfh phenotype (i.e., ‘‘pre-Tfh cell’’)
characterized phenotypically as CD4+CXCR5hiPD1lo, which
migrate the T and B cell border of secondary lymphoid organs
and interact with their cognate antigen-primed B cells [17]. This
T:B cell interaction typically results in the Tfh cells producing
optimal amounts of IL-21, and in the B cells differentiating into
early short-lived extrafollicular antibody secreting cells or migrat-
ing into the follicles and forming GCs. With additional signals
provided by Tfh cells in GCs, B cells mature and differentiate into
long-lived plasma cells (PCs) secreting high affinity antibodies or
into memory B cells. Due to the importance for PCs secreting high
affinity antibodies and memory B cells in vaccine-induced
immunity, the development of Tfh cells and CG B cells is critical
for vaccine-induced protection against future exposures. In the
context of RABV-specific vaccination in post-exposure settings,
the rapid induction of extrafollicular B cell responses may also be
critical to prevent infection of the CNS, especially in cases where
treatment is delayed after exposure to a potentially infected
animal. As such, understanding factors that generate short- and
long-term anti-viral B cell responses will help design more
efficacious RABV vaccines for use in humans.
Cytokines present at the time of antigen exposure influence T
and B cell activation and GC formation and, therefore, also affect
the outcome of vaccination. IL-21 [18,19] is a type 1 cytokine that
is a member of the common c-chain receptor family, which also
includes IL-2, IL-4, IL-7, IL-9, and IL-15. It is produced primarily
by activated Tfh and Th17 cells and has pleiotropic effects
throughout innate and adaptive immunity [reviewed in [20]]. The
role for IL-21 in regulating Tfh and B cell functions was originally
identified using model antigens [21–23]. In addition, the role for
IL-21 in immunity and protection against helminth [24], viral
[25,26] and bacterial [22] infections has been studied. IL-21 is a
key mediator for the control of persistent viral infections in mouse
models of LCMV [27–29] and hepatitis B virus [30], or in humans
infected with HIV [31–33] or HIV in combination with the 2009
H1N1 influenza virus vaccine [34]. However, the complexity and
diversity of persistent infections makes it is difficult to pinpoint the
effects of IL-21 on anti-viral B cells versus CD8+ T cells, both of
which can contribute the control of many chronic infections [35].
Conversely, B cells play a critical role for clearance of most acute
viral infections and for the efficacy of vaccines against most
vaccine-preventable diseases. Clearance of RABV infections relies
strictly on B cell-mediated effector functions, but not CD8+ T cells,
for protection, making RABV infection an excellent mouse model
to pinpoint the role for IL-21 in vaccine-induced immunity against
RABV infections and potentially for other pathogens that rely
solely on B cells for protection. In this report, our preliminary data
indicate that IL-21 is critical for the development of effective
vaccine-induced primary antibody responses against RABV
infections by influencing GC B cells or PC generation in a
vaccine dose-dependent manner, while also showing IL-21 is
dispensable for RABV-specific secondary antibody responses when
a primary antibody response develops.
Materials and Methods
Ethics statement
All animal work was reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC) of Jefferson Medical
College, Thomas Jefferson University. Work was completed in
accordance with international standards [Association for Assess-
ment and Accreditation of Laboratory Animal Care (AAALAC)]
and in compliance with Public Health Service Policy on Humane
Care and Use of Laboratory Animals, The Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health
(NIH).
Viral vaccine, challenge rabies virus and mice
The construction of the live RABV-based vaccine (rRABV) used
in this study was described elsewhere and was previously named
SPBN [9,36,37]. This vaccine is a molecular clone derived from
the attenuated SAD-B19 vaccine strain of RABV. Virus stocks
were propagated on baby hamster kidney cells and then
concentrated and purified over a 20% sucrose cushion. The
challenge virus used was the pathogenic Challenge Virus Strain-
N2c (CVS-N2c), which is a mouse-adapted sublclone of CVS-21
RABV [38]. CVS-N2c was initially propagated in neonatal mouse
brains and then passaged once in-vitro on a neuroblastoma cell
line (NA cells). The titer of CVS-N2c required to kill unvaccinated
mice was determined experimentally by inoculating serial ten-fold
dilutions into naı¨ve immune-competent mice [39] i.m. and then
observing mice daily for clinical neurological symptoms of rabies.
The titer required to kill unvaccinated mice within 8 days post-
infection, which is typical for CVS-N2c [9,10], was determined to
be 105 focus forming units (ffu)/mouse. Cryopreserved embryos of
mice deficient in the IL-21 receptor (B6;129-IL21r tm1Wjl/Mmucd);
#015505-UCD) [39] were obtained from the Mutant Mouse
Regional Resource Centers (NIH) and implanted and bred in-
house at Thomas Jefferson University in a pathogen-free animal
facility. Control C57BL/6 mice were obtained from the Frederick
National Laboratory for Cancer Research (NCI).
Author Summary
Over two-thirds of the world’s population lives in regions
where rabies is endemic, resulting in over 15 million
people receiving post-exposure treatment. A person,
disproportionately a child, dies of rabies every 20 minutes
and the cost of rabies prevention exceeds $1 billion US
dollars per year. The development of a single-dose human
rabies vaccine would greatly reduce the burden of rabies
globally by lowering the cost associated with rabies
vaccination and saving lives. Understanding how B cells
develop to produce protective virus neutralizing antibod-
ies would greatly help to achieve the goal of developing a
single-dose vaccine. In this report, we show that IL-21 is
critical for the induction of primary vaccine-induced anti-
RABV G antibody titers and that the effects of IL-21 are
highly dependent on the dose of vaccine administered. In
our model of rabies immunogenicity and protection, the
lack of IL-21 receptor influenced the detection of B cells in
germinal centers in lymph nodes or of plasma cells in bone
marrow after immunization with low or high doses of
vaccine, respectively. Overall, these preliminary results
indicate that IL-21 has the potential to influence B cell
development and functions in the context of rabies
vaccine-induced immunity and protection.
IL-21 in Rabies Virus Vaccine-induced Immunity
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Antibodies
The following antibodies where purchased from BD Bioscienc-
es, unless otherwise noted, and used for flow cytometry staining:
APC-Cy7-B220 (clone RA3-6B2), PerCP-CY5.5-CXCR5 (clone
2G8), APC-CD138 (clone 281-2), PE-Cy7-CD95/Fas (clone Jo2),
FITC-GL7, eFluor 450-CD4 (clone RM4–5, eBioscience), PE-
PD1 (clone J43, eBioscience), Alexa Fluor 700-CD38 (clone 90,
eBioscience), rat anti-mouse CD16/32 (FcBlock; Pharmingen).
Immunization, pathogenic challenges, sample collection
and ELISA and virus neutralizing antibody assays to
measure anti-RABV antibody titers
Groups of 6- to 10-week-old female IL-21R2/2 or wild-type
C57BL/6 mice were inoculated intramuscularly (i.m.) with 103 or
105 focus forming units (ffu)/mouse with rRABV or an equivalent
volume of PBS as controls. Five weeks post-immunization, mice
were challenged i.m. with 105 ffu/mouse with CVS-N2c and then
observed for three weeks for clinical signs of rabies. Mice were
euthanized at the onset of neurological symptoms. At various times
post-immunization and challenge, blood was collected retro-
orbitally. Three-fold serial dilutions of sera were tested by ELISA
to determine RABV G-specific IgG antibodies as described [10]
and reported as the reciprocal serial dilution. Data represented
two independent experiments (N = 9–11 mice per group). To
measure virus neutralizing antibody titers, the Rapid Fluorescent
Foci Inhibition Test (RFFIT) was completed on pooled sera from
two independent experiments as described previously [16,40,41].
Immunization, sample collection and flow cytometry
analyses of T and B cell subsets from lymph nodes and
bone marrow
Groups of 6- to 10-week-old female IL-21R2/2 or wild-type
mice were inoculated i.m. with 103 or 105 ffu/mouse with rRABV
or PBS/naive as controls. Draining lymph nodes and bone marrow
cells were collected 7 and/or 14 days post-immunization. Single cell
suspensions (106 cells/sample) were incubated with rat anti-mouse
CD16/32 (1 ug/106 cells) in fluorescence-activated cell sorter
(FACS) buffer (PBS supplemented with 2% fetal bovine serum) for
1 h on ice. Cells were washed twice with FACS buffer and
incubated with fluorescently conjugated antibodies (0.2 ug/106
cells) for 30 min at RT in the dark. Cells were subsequently washed
2 times with FACS buffer and fixed in 2% paraformaldehyde in
PBS for 30 minutes. Flow cytometry was completed using FACScan
(BD LSRII) and analyzed by FlowJo software. Data represents
samples completed in duplicate (N = 3–5 mice) [16].
Statistical analysis
Kaplan-Meier survival curves were analyzed by the log rank test;
*p =,0.05 indicates significant survivorship between two immuniza-
tion groups [9,10]. Statistical difference between two groups of data
was compared using an unpaired, two-tailed t test and data is presented
at the mean6 SEM; *p,0.05, **p = 0.01–0.001, ***p#0.001 [9,10].
Results
IL-21 is critical for primary but not secondary antibody
responses to live RABV-based vaccination
Cytokines present at the time of immunization have the ability
to affect the outcome of vaccine-induced B cell responses. Due to
the importance for IL-21 in promoting effective T-dependent B
cell responses [21,22], we examined the requirement for IL-21R
signaling in the generation of antibodies in a mouse model of
RABV immunogenicity and protection using a mouse model of
IL-21R-deficiency. These mice, designated here as IL-21R2/2
mice, lack the IL-21R extracellular and transmembrane domains
but show normal lymphoid development [39]. T and B cells exhibit
similar proliferative responses to CD3-speficic antibodies or LPS,
respectively, when compared to wild-type controls [39]. As a group,
IL-21R2/2mice immunized with a low dose of a live recombinant
RABV-based vaccine (rRABV) (103 ffu/mouse) showed only low
levels of anti-RABV G antibodies that were not significantly
different from PBS-immunized mice at all time points tested post-
immunization (Figure 1, left panels, a–e), although at least three IL-
21R2/2 mice developed anti-RABV antibodies by day 28 post-
immunization (Figure 1B). The seroconversion of these three IL-
212/2 mice may explain the limited protection observed in the
pathogenic challenge experiments described later in this report.
Wild-type mice immunized with the same dose of rRABV showed
significant levels of anti-RABV G antibodies as early as 7 days post-
inoculation compared to rRABV-immunized IL-21R2/2 mice,
and these antibody responses continued to increase through day 21
post-immunization. VNA titers detected 28 days post-immunization
(Figure 1C) are consistent with the antibody titers detected by
ELISA (Figure 1B) indicating anti-RV antibody titers detected by
ELISA are representative of the ability for vaccine-induced
antibodies to neutralize rabies virus. IL-21R2/2 mice immunized
with a higher dose of rRABV (105 ffu/mouse) showed significantly
reduced anti-RABV antibody responses when compared to wild-
type mice also immunized with 105 ffu/mouse of rRABV (Figure 1,
right panels, f–j). Together, this data indicates that IL-21 is critical
for the induction of optimal primary anti-RABV antibody
responses, especially when low doses of vaccine are used.
We next wanted to evaluate the effect of IL-21 on vaccine-
induced antibody recall responses and protection against patho-
genic RABV challenge. Five weeks post-immunization with
rRABV, mice from Figure 1 were challenged with 105 ffu/mouse
of a highly pathogenic mouse-adapted RABV strain (Challenge
Virus Strain-N2c; CVS-N2c) [38], which typically kills naı¨ve mice
within 8 days post-infection [9,10]. Consistent with the low
antibody titers detected during the primary antibody response,
significantly less anti-RABV antibodies were detected three or five
days post-challenge in IL21R2/2 mice immunized with 103 ffu/
mouse of rRABV compared to the antibody recall response
detected in wild-type mice (Figure 2, panels a and b, and
Figure 2B) and antibody recall titers were not significantly different
from PBS-immunized/CVS-N2c-challenged mice (Figure 2, e).
Only 40% of IL-21R2/2 mice immunized with 103 ffu/mouse of
rRABV were protected against pathogenic RABV challenge, while
all wild-type mice that were similarly immunized were protected
against challenge (Figure 3, left panel). As expected, those mice with
higher antibody titers showed protection compared to mice with
lower antibody titers (Figure 2B). Conversely, an antibody recall
response was induced in IL-21R2/2 mice immunized with 105
ffu/mouse of rRABV within three days post-challenge with CVS-
N2c at levels equivalent to rRABV-immunized wild-type mice
(Figure 2, panels c and d) and all immunized IL-21R2/2 mice
were protected against pathogenic RABV challenge (Figure 3, right
panel). Taken together, IL-21 is required for optimal primary
(Figure 1) but not secondary (Figure 2) antibody responses to RABV
vaccination. Furthermore, IL-21 is required for protection against
pathogenic RABV in a vaccine dose-dependent manner (Figure 3).
IL-21 is dispensable for Tfh formation at all vaccine doses
tested but required for optimal GC B cells in a vaccine
dose-dependent manner
Next we wanted to determine whether the impaired primary
anti-RABV antibody response in IL-21R2/2 mice was due to an
IL-21 in Rabies Virus Vaccine-induced Immunity
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Figure 1. IL-21 signaling promotes optimal primary antibody
responses induced by live RABV-based vaccination. A) IL-21R2/
2 or wild-type C57BL/6 mice were immunized i.m. with 103 (left panels
a–e) or 105 (right panels f–j) ffu/mouse of rRABV and blood collected at
the indicated time points. Four serial three-fold dilutions of sera were
analyzed by ELISA to determine anti-RABV G antibody titers and
presented as OD490 of the reciprocal serial dilution. For comparison,
sera from PBS-immunized IL-21R2/2 or wild-type mice (panel k) were
tested in parallel and representative ELISA data for day 21 post-
immunization is shown. B) Antibody titers for individual mice
immunized with 103 ffu/mouse [from Figure 1A(e)] are shown to
indicate that at least three of the ten IL-21R2/2 mice seroconverted
against RABV G by day 28 post-immunization. C) VNA titers were
measured from pooled sera collected 28 days post-immunization by
RFFIT and expressed as International Units (IU/ml). The average of two
independent experiments is shown. Statistical difference in antibody
titers by ELISA between two groups of data was determined using an
unpaired, two-tailed t test and data is presented at the mean 6 SEM.
*p,0.05, **p= 0.01–0.001, ***p#0.001. (N = 9–11 mice per group from
two independent experiments). (ffu = focus forming units; OD=optical
density).
doi:10.1371/journal.pntd.0002129.g001
Figure 2. IL-21 signaling is dispensable for antibody recall
responses to secondary RABV challenge. A) Five weeks post-
immunization, mice immunized in Figure 1 with 103 (left panels a and b)
or 105 (right panels c and d) ffu/mouse were challenged with 105 ffu/
mouse of pathogenic Challenge Virus Strain-N2c and sera analyzed 3
and 5 days post-challenge by ELISA for anti-RABV G antibody recall
responses as described in Figure 1. PBS-immunized IL-21R2/2 and
wild-type mice were also tested in parallel and a representative ELISA
data is shown in panel e. B) Antibody titers for individual mice
immunized with 103 ffu/mouse rRABV and then challenged [from
Figure 2A(b)] are shown to indicate an antibody recall response against
RABV G by day 3 post-challenge in a minimum number of IL-21R2/2
mice. Mice that survived challenged are shown with a green icon, mice
that did not survive challenge are shown with a red icon. Statistical
difference in antibody titers by ELISA between two groups of data was
determined using an unpaired, two-tailed t test and data is presented at
the mean 6 SEM. *p,0.05, **p= 0.01–0.001, ***p#0.001. (N= 9–11
mice per group from two independent experiments). (p.c. = post-
challenge; ffu = focus forming units; OD=optical density).
doi:10.1371/journal.pntd.0002129.g002
IL-21 in Rabies Virus Vaccine-induced Immunity
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overall defect in the generation of Tfh and/or GC B cells. Lymph
nodes from IL-21R2/2 or wild-type mice were collected 7 or 14
days post-immunization with 103 or 105 ffu/mouse of rRABV or
PBS alone to determine the influence of IL-21 on Tfh and B cell
populations. Representative gating strategies [17,42] to identify
CD4+ T cells from the total live lymph node cultures (Figure 4A)
or Tfh (CD4
+CXCR5hiPD1hi) cells from the CD4+ T cell
populations (Figure 4B) are shown. A significant increase in the
number of CD4+ T cells displaying a Tfh phenotype was detected
in IL-21R2/2 mice 14 days post-immunization with 103 or 105
ffu/mouse rRABV compared to similarly immunized wild-type
mice (Figure 4C and Figure 4D, respectively). However, the
formation of optimal GC B cells appears to be dependent on the
dose of vaccine administered (Figure 5). Representative gating
strategies [22,43,44] to identify B220+ B cells from the total live
lymph node cultures (Figure 5A) or GC B cells
(B220+GL7hiCD95/Fashi) from the B220+ B cell population
(Figure 5B) are shown. IL-21R2/2 mice immunized with a low
dose of vaccine failed to induce optimal GC B cell formation
compared to wild-type mice 14 days post-immunization, as shown
by a significant decrease in the number of GC B cells in IL-21R2/
2 mice compared to wild-type mice (Figure 5C). However, a
significant increase in the number of GC B cells was detected in
IL-21R2/2 mice immunized with 105 ffu/mouse of rRABV
compared to wild-type mice 14 days post-immunization
(Figure 5D). The data indicates that the suboptimal primary
antibody responses detected in IL-21R2/2 mice immunized with
103 ffu/mouse of rRABV appears to be due to the lack of GC B
cell formation, while the suboptimal primary antibody response
detected in IL-21R2/2 mice immunized with 105 ffu/mouse
most likely does not result from a defect in Tfh or GC B cell
development.
IL-21 is dispensable for memory B cells formation but
required for plasma cell generation in response to live
RABV-based vaccination
Our analysis above shows that IL-21R signaling is dispensable
for the formation of the Tfh and GC B cell populations in response
to higher doses of rRABV, indicating that other B cell types are
more likely responsible for the suboptimal primary antibody titers
detected in IL-21R2/2 mice immunized with 105 ffu/mouse.
Since IL-21 can also influence the balance between the generation
of memory B cells and PCs [24,45–47], we investigated the role for
IL-21R signaling to regulate memory B cell and PCs populations
in response to RABV vaccination. Figure 6A and Figure 6B show
representative gating strategies [48–50] to identify the memory
B220+ B cells (CD38+CD1382) from the lymph node and PC
(B220loCD138+) populations from the bone marrow from mice
immunized with 103 or 105 ffu/mouse of rRABV or PBS alone.
The presence or absence of IL-21R does not appear to influence
the development of memory B cells in mice immunized with 103
ffu/mouse of rRABV (Figure 6C). However, the percentage of
memory B cells was significantly increased in the lymph node cell
cultures from IL-21R2/2mice immunized with 105 ffu/mouse of
rRABV as early as 7 days post-immunization compared to
immunized wild-type mice (Figure 6C). By day 14 post-immuni-
zation, similar memory B cell populations were measured (data not
shown), indicating that IL-21 is not required for the formation of
memory B cells in response to live RABV-based vaccination. This
is consistent with the findings in Figure 1 and Figure 2 indicating
that IL-21 is dispensable for secondary antibody responses against
RABV infection when a primary antibody response develops.
However, the percentage of PCs was reduced in the bone marrow
of IL-21R2/2 mice immunized with 105 ffu/mouse compared to
rRABV- or PBS-immunized wild-type mice 14 days post-
immunization (Figure 6D), consistent with the suboptimal primary
antibody titers detected in IL-21R2/2 mice.
Discussion
Current rabies PEP regimens are based on multiple doses of
inactivated RABV-based vaccines administered intramuscularly or
intradermally. In cases of severe exposure, rabies immune globulin
(RIG) is administered [51–53]. The development of a single-dose
vaccine would greatly benefit human rabies prevention by
reducing the cost of vaccination and saving lives. Understanding
immune parameters that influence the magnitude and/or quality
of anti-RABV antibody responses may lead to more effective
single-dose vaccines [54]. Correlates of protection against rabies
Figure 3. IL-21 signaling is important for protection against RABV challenge after low-dose vaccination. Immunized (Figure 1) and
challenged (Figure 2) mice were monitored daily for 28 days post-challenge for clinical signs of rabies and euthanized at the first neurological
symptoms of RABV infection (103 ffu/mouse left panel; 105 ffu/mouse, right panel). Kaplan-Meier survival curves were analyzed by the log rank test;
*p,0.05. (N = 9–11 mice per group from two independent experiments). (ffu = focus forming units).
doi:10.1371/journal.pntd.0002129.g003
IL-21 in Rabies Virus Vaccine-induced Immunity
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infections are defined as virus neutralizing antibodies directed
against the single viral transmembrane glycoprotein (G)
[15,52,54,55]. CD8+ T cells do not appear to be important for
the clearance of RABV infections [56]. Protection against RABV
infection typically requires CD4+ T cell help [56–60], although we
recently showed that this requirement is not absolute and that
protection against pathogenic RABV challenge can be afforded in
mice devoid of all T cells (TCRbd2/2 mice) vaccinated with a
matrix gene-deleted RABV-based vaccine (rRABV-DM) [16].
Furthermore, we show that mice immunized with rRABV-DM
also induce antibodies by T cell-dependent extrafollicular B cell
responses before GC-derived B cells are detected. Together, our
previous work identified multiple pathways of B cell development
that can be exploited to make more efficacious RABV-based
vaccines for use in humans. Nonetheless, very little information is
available on how effective B cells develop in response to live
RABV-based vaccination. IL-21 is a pleotropic cytokine that is
produced by NKT cells and CD4+ T cells, most notably Th17 and
Tfh cells. IL-21 binds to the IL-21R on a wide variety of cells
involved in innate immunity, including DCs, NK cells, NKT cells,
and macrophages, as well as on cells involved in adaptive
immunity, such as B cells and CD4+ or CD8+ T cells [reviewed
in [20]]. Due to its multiple roles in innate and adaptive immunity,
IL-21 has the potential to influence the quality and magnitude of
vaccine-induced immunity to acute viral infections. Here we used
a mouse model of IL-21R-deficiency to evaluate the role for IL-
21R signaling in vaccine-induced protection against RABV; i.e.,
an acute viral infection that relies on B cells for protection that has
implications for global public health initiatives.
In this report, we showed that IL-21R signaling is critical for the
generation of optimal primary anti-RABV antibody responses to
vaccination. Primary anti-RABV antibody titers were significantly
reduced in immunized IL-21R2/2 mice compared to wild-type
mice at almost all time points tested post-immunization, suggesting
IL-21R signaling plays important roles throughout RABV-specific
primary B cell responses. Nonetheless, IL-21R signaling appears to
influence immunity in a vaccine dose-dependent manner, which is
consistent with findings by others suggesting the influence of IL-21
is dependent on the model studied [22,61]. Indeed, significantly
less IL-21R2/2 mice immunized with low-dose vaccination were
protected against pathogenic challenge compared to wild-type
mice while all IL-21R2/2 and wild-type mice immunized with
high-doses of vaccine survived challenge similarly. Despite the
differences in protection elicited in IL-21R2/2 mice immunized
Figure 4. IL-21 is dispensable for Tfh cell development in response to rRABV-based vaccination. IL-21R2/2 or C57BL/6 mice were
immunized i.m. with a single dose of 103 or 105 ffu/mouse with rRABV and Tfh cell development was analyzed at the indicated time points post-
immunization. A, Representative gating strategy from IL-21R2/2 or C57BL/6 mice immunized with rRABV or an equal volume of PBS as a control to
identify CD4+ T cells from total live draining lymph node cells. B, Representative gating strategy from IL-21R2/2 or wild-type mice immunized with
rRABV or PBS to identify Tfh (CD4
+CXCR5hiPD1hi) cells from the CD4+ T cell population. C and D, Percentage of Tfh cells in the total CD4
+ T cell
population in lymph nodes was determined in IL-21R2/2 or C57BL/6 mice 7 and 14 days post-immunization with 103 (C) or 105 (D) ffu/mouse rRABV
or PBS. Statistical difference in T cell data between two groups of data was determined using an unpaired, two-tailed t test and data is presented at
the mean 6 SEM. *p,0.05, **p= 0.01–0.001, ***p#0.001; (N = 5 mice per group).
doi:10.1371/journal.pntd.0002129.g004
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with different doses of vaccine, it appears that IL-21 is critical for
the generation of optimal RABV-specific primary B cell responses.
One potential explanation for the suboptimal primary antibody
responses observed in immunized IL-21R2/2 mice compared to
immunized wild-type mice might be that GC B cells failed to form
in IL-21R2/2 mice, therefore, the GC B cell compartment was
analyzed in mice immunized with different doses of vaccine. GC-
derived B cells were reduced in IL-21R2/2 mice immunized
with a low dose of vaccine compared to similarly immunized wild-
type mice, indicating that IL-21 is required for optimal GC B cell
formation in response to low-dose RABV-based vaccination. On
the other hand, GC-derived B cells expanded in IL-21R2/2
mice immunized with a high dose of vaccine compared to similarly
immunized wild-type mice, indicating that IL-21 is dispensable for
GC B cell formation after high-dose vaccination with rRABV-
based vaccines. Furthermore, the data indicates that factors other
than IL-21 were responsible for GC B cell formation in IL21R2/
2 mice immunized with higher doses of vaccine. Multiple signals
lead to B cell activation and functions. These signals can come
from BCR or Toll-like receptor (TLR) ligation, TNF superfamily
receptor engagement (eg., via BAFF and APRIL) or cytokine
signaling. Furthermore, B cell activation is contextual, meaning B
cells are differentially activated in the presence of different signals
at the time of antigen exposure. Due to the repetitive display of
rabies antigen on the surface of infectious particles, the potential
exists that cross-linking BCRs and/or TLRs on the surface of B
cells overcame the requirement for IL-21R signaling in B cell
activation when high doses of vaccine are administered. The
influences of these and other B cell signaling events in the context
of RABV-based vaccine-induced B cell activation were not directly
measured in these studies and remain to be elucidated. Nonethe-
less, based on the results reported here, it appears that IL-21R
signaling is important for optimal primary vaccine-induced
antibody responses to RABV vaccination especially when low
doses of vaccine are administered.
As noted above, a rapid antibody response is critical for rabies
PEP to neutralize virus before it reaches the CNS. We have
recently shown that RABV-based vaccines are able to induce early
and rapid T cell-dependent extrafollicular antibody responses
before GC B cells are formed [16]. These early pre-GC B cell
responses contributed to the protection against pathogenic RV
challenge early post-immunization, which is an important
attribute for PEP [16]. In the studies described in this report, we
detected a significant reduction in antibody titers in IL-21R2/2
Figure 5. IL-21 promotes optimal GC B cell development in a vaccine dose-dependent manner. Draining lymph node cells from IL-21R2/
2 or wild-type C57BL/6 mice immunized in Figure 4 were analyzed for the presence of B cells displaying a GC phenotype (B220+GL7hiCD95/Fashi). A,
Representative gating strategy from IL-21R2/2 or C57BL/6 mice immunized with rRABV or PBS to identify B220+ B cells from total live lymph node
cells. B, Representative gating strategy from IL-21R2/2 or wild-type mice immunized with rRABV or PBS to identify GC B cells. C and D, Number of GC
B cells per 100,000 draining lymph node cells was determined in IL-21R2/2 or wild-type mice immunized with 103 (C) or 105 (D) ffu/mouse 7 or 14
days post-immunization with rRABV or PBS alone. Statistical difference in GC B cell data between two groups of data was determined using an
unpaired, two-tailed t test and data is presented at the mean 6 SEM. *p,0.05, **p= 0.01–0.001, ***p#0.001; (N = 5 mice per group); (ffu = focus
forming units).
doi:10.1371/journal.pntd.0002129.g005
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mice as early as 5 days post-immunization with a high dose of
rRABV compared to immunized wild-type mice, suggesting that
IL-21 may be influencing the outcome of extrafollicular antibody
responses in the context of RABV vaccination, although this was
not directly studied in this report. Nonetheless, the frequency of
Tfh and GC B cells was similar in IL-21R2/2 mice compared to
wild-type mice 7 days post-immunization and, therefore, it would
appear that the early suboptimal antibody responses in IL-21R2/
2 mice may be due to impaired extrafollicular PCs directly and
not through impaired Tfh or GC B cell formation. This is
consistent with the findings that IL-21 can promote Blimp-1
expression and PC development [47], IL-21- or IL-21R-deficiency
decreases extrafollicular PCs in a model of NP-KLH immunity
[62], and that IL-21 acts on early stages of B cell differentiation
before GC or PC B cells are formed [42]. Finally, IL-21 has been
reported to be important for Tfh cell maintenance but not
formation. Together, existing data suggests that IL-21R2/2
signaling influences early events in pre-GC B cell development in
the context of RABV vaccination [22].
IL-21 can also influence the balance of B cell differentiation into
memory B cells or PCs [45–47]. The specific role for IL-21 in
memory B cell responses is not completely clear and appears to
rely on the type of antigen used and the model studied [61,62]. In
the context of RABV vaccination, IL-21R signaling was not
required for the generation of B cells displaying a memory B cell
phenotype in IL-21R2/2 mice immunized with either vaccine
dose. This is consistent with our finding showing that IL-21R
signaling is not required for optimal secondary anti-RABV G
antibody titers after challenge with pathogenic RABV. However,
we detected a decrease in the number of PCs in IL-21R2/2 mice
immunized with either dose of vaccine compared to wild-type
mice. We cannot determine whether the slightly suboptimal PC
subset detected in IL-21R2/2 mice immunized with low doses of
vaccine was indirectly a result of impaired GC B cell development
or directly as a result of impaired PC formation itself. However, in
mice immunized with a high dose of vaccine where we observed
an expansion of GC-derived B cells in IL-21R2/2 mice, we also
observed a decrease in PCs in the bone marrow compared to wild-
type mice, indicating that IL-21 acts directly on the formation of
PCs. Together, the data shows that IL-21 influences the balance
between memory and PC B cell formation in the context of RABV
vaccination.
Despite the impaired primary antibody response and PC B cell
formation in immunized IL-21R2/2 mice, we detected an
expansion of CD4+ T cells displaying a pre-Tfh (data not shown),
Tfh cell and GC B cell phenotype in IL-21R2/2 mice compared
Figure 6. IL-21 is dispensable for memory B cells but required for optimal PC formation. IL-21R2/2 or C57BL/6 mice were immunized i.m.
with a single dose of 103 or 105 ffu/mouse with rRABV and memory B cell or PC populations were analyzed 7 or 14 days post-immunization,
respectively. A, B220+ B cells were gated from the total live draining lymph node cell population as described in Figure 5. Representative gating
strategy from IL-21R2/2 or C57BL/6 mice immunized with rRABV or PBS to determine memory B cells (B220+CD38+CD1382) from total B220+ B cells
in the draining lymph node. B, Representative gating strategy from IL-21R2/2 or C57BL/6 mice immunized with rRABV or PBS to identify PCs
(B220loCD138+) from the total cells in the bone marrow. C, Percentage of B cells displaying a memory B cell phenotype in the lymph node was
determined in IL-21R2/2 or C57BL/6 mice immunized with 103 or 105 ffu/mouse at 7 days post-immunization with rRABV or PBS. D, Percentage of
PCs in the BM cell population was determined from IL-21R2/2 or C57BL/6 mice immunized with 103 or 105 ffu/mouse at 14 days post-immunization
with rRABV or PBS. Statistical difference in B cell data between two groups of data was determined using an unpaired, two-tailed t test and data is
presented at the mean 6 SEM. *p,0.05, **p = 0.01–0.001, ***p#0.001; (N = 5 mice per group).
doi:10.1371/journal.pntd.0002129.g006
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to wild-type mice at 14 days post-immunization. The expansion of
GC B cells and Tfh cells in the absence of IL-21R signaling was
also shown by King I.L. et al in a model of Heligmosomoides polygyrus
immunity [24], suggesting that IL-21R signaling may not be
necessary for the generation of these cell types in response to a
wide range of pathogens or vaccination. Furthermore, the increase
in GC B cells and Tfh cells in H. polygyrus-infected or RABV-
vaccinated IL-21R2/2 mice suggests that IL-21R signaling may
play an inhibitory role in the development of T and B cells in the
context of some pathogens, which is consistent with the ability for
IL-21 to activate or inhibit immune function depending on the
antigen and available co-stimulatory signals [20]. The expansion
of Tfh and GC B cells in IL-21R2/2 mice compared to wild type
mice is also consistent with the finding that IL-21 has the ability to
mediate apoptosis in primary resting and activated murine B or to
promote apoptosis or growth arrest for non-specifically activated B
cells [63]. Alternatively, the elevated number of GC Tfh cells could
be a result of the lack of PC that developed in the IL21R2/2
mice. Pelletier et al described a negative regulatory feedback-loop
in which antigen-specific PCs negatively regulate antigen-specific
Tfh cell development and function [64]. In this report, they also
observed a significant expansion of Tfh cells and GC B cells in the
absence of PC development. Together, the role for IL-21 in the
homeostatic balance of T and B cell development in the context of
infectious diseases appears to be important and remains to be fully
elucidated.
Additional studies are needed to identify the exact cell type(s)
responsible for the affects described in this report. While we
speculate that B cell-intrinsic IL-21R signaling is responsible for
the induction of optimal anti-RABV antibody responses, we
cannot rule out the influence of other cell types that also express
IL-21R. IL-21 has the ability to influence the function of
macrophages, NK cells and NKT cells by affecting survival/
apoptosis, antigen processing, and cytokine secretion [reviewed in
[20]]. The function of these cells of the innate immune system may
indirectly be affecting the outcome of B or T cell functions in the
context of RV vaccination. Nonetheless, IL-21 has the potential to
influence a wide range of B cell functions and pathways. Our
preliminary data indicates that IL-21 is critical for the formation of
optimal vaccine-induced primary antibody responses and demon-
strates an important role for IL-21 in the generation of vaccine-
induced immunity against RABV infection and perhaps other
acute infections that rely on B cell-mediated effector functions for
protection.
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